GT-1 is a novel siderophore cephalosporin antibiotic, and is being developed for the treatment of MDR Gram-negative bacterial infections.  GT-1 is actively transported into Gram-negative cells by exploiting iron uptake systems that use low molecular weight iron-binding molecules known as siderophores to transport iron into the cells.  This “Trojan Horse” strategy facilitates uptake of GT-1 into the bacterial periplasmic space in high concentrations where GT-1 binds to its penicillin-binding protein targets and disrupts cell wall synthesis, leading to cell death. This increased transportation into bacterial cells potentiates activity against Gram-negative bacteria, including activity against MDR Acinetobacter spp. and P. aeruginosa.  All IND-enabling studies have been completed for GT-1 and clinical studies will be initiated in 2019


ECCMID | Amsterdam, Netherlands | April 2019

One poster and one oral presentation demonstrate the mechanism of action and efficacy driver of GT-055, in combination with GT-1


ASM MICROBE | Atlanta, GA | June 2018

Twelve posters and two oral presentations summarize nonclinical studies of Geom's novel cephalosporin GT-1 and novel beta-lactamase inhibitor GT-055

ASM BIOTHREATS | Baltimore, MD | February 2018

GT-1 Has Potent Activity against Select Biothreat Pathogens Either Alone or in Combination with a beta-lactamase Inhibitor (GT-055)

ASM MICROBE | New Orleans, LA | June 2017

Pharmacokinetic-Pharmacodynamic Analyses for GT-1 Using Data    from a Murine-Thigh Infection Model

Site map:

Contact Us